<DOC>
	<DOCNO>NCT00742872</DOCNO>
	<brief_summary>The purpose study determine whether Mosapride , agent act serotonin receptor gastrointestinal tract , effective treatment constipation-predominant irritable bowel syndrome ( C-IBS ) .</brief_summary>
	<brief_title>Randomized Trial Mosapride Versus Placebo Treatment Constipation-Predominant Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Mosapride</mesh_term>
	<criteria>Rome III Criteria IBS : Patients must recurrent abdominal pain discomfort least 3 day per month previous 3 month associate 2 follow : Relieved defecation Onset associate change stool frequency Onset associate change stool form appearance In addition , patient experience least two follow symptom least 25 % time [ 11 ] : Altered stool frequency ( &lt; 3 bowel movement per week ) Altered stool form ( lumpy/hard i.e . Bristol type IIII [ see appendix 1 ] ) Altered stool passage ( strain , urgency , feel incomplete evacuation ) Passage mucus , bloating , feel abdominal distension Previous allergy mosapride Nocturnal Symptoms ( pain middle night , nocturnal symptom suggest organic disease ) Age &lt; 18 year History bloody stool melena Diarrhea ( &gt; 3 bowel movement per day ) Constitutional symptom ( fever , weight loss ) Severe constipation ( &lt; 1 bm/week ) Pregnancy lactation Patients history cardiac arrhythmia QT prolongation baseline ECG Chronic laxative use dependence Patients previous history congenital heart disease Patients previous history hypokalemia hyperkalemia Patients take follow class drug : HIV antiviral , macrolides , antiarrhythmic , azole drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Mosapride</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Constipation</keyword>
</DOC>